Biotech Catalysts This Week: 2 FDA Decisions, 12 Trial Completions and 2 Earnings Reports (Oct 25-Nov 1, 2026)

· 8 min read

Two PDUFA dates headline the week, AGIO mitapivat in sickle cell disease on 2026-11-01 and INO-3107 in recurrent respiratory papillomatosis on 2026-10-30, alongside 12 trial primary completion dates spanning sponsors from NVS to AMGN. The broader week carries 10 new financing filings and 12 key SEC filings against a single prior-week delay, QNRX pushing back QRX003, following IONS Hibsago approval and two trials marked completed at VNDA and GILD.

At a glance: this week 2 FDA decision dates, 12 Phase 2 or 3 trials reaching primary completion, 2 earnings reports and 10 new financing filings. Last week: 1 timeline pushed back, 1 FDA decision, 8 new timelines announced and 12 key SEC filings.

🔄 What Changed Last Week

Timelines pushed back or discontinued, in the companies’ own words:

  • QNRX pushed back QRX003 from first half of 2026 to by the end of 2026. Before (2026-01-20): “Enrollment in both studies is expected to be completed in the first half of 2026, with top-line data anticipated in the second half of 2026.” Now (2026-10-20): “Quoin expects to complete recruitment of all 20 participants in CL-QRX003-004 by the end of 2026 and report topline data in the second quarter of 2027.” SEC filing

All pushed-back and discontinued milestones →

New timelines announced in press releases:

  • EIKN, EIK1003: the second half of 2027. “Eikon is currently enrolling an additional Cohort 1D evaluating EIK1003 in combination with paclitaxel and platinum-based chemotherapy, for which initial results are expected in…” SEC filing
  • BOLT, PRA-216: beginning in the second quarter of 2027 and continuing through the fourth quarter of 2027. “Phase 2 development in asthma, COPD, and atopic dermatitis has been initiated, with a Phase 2 study in EoE planned, and with patient data from all four trials expected beginning…” SEC filing
  • ELOX, EXPRESS: in the third quarter of 2027. “First patient dosing is expected in the third quarter of 2027, with topline data expected in the first half of 2029.” SEC filing
  • ARGX, EMVIGORATE and EMNERGIZE: in the second half of 2027. “Topline results from Phase 3 EMVIGORATE and EMNERGIZE studies in CIDP anticipated in the second half of 2027” SEC filing
  • PHAR, leniolisib: November 2026. “Clinical updates At ESID 2026, Pharming presented positive Phase II data for leniolisib in patients with genetically defined primary immunodeficiencies (PIDs) with immune…” SEC filing
  • VCRE, ASPIRE: mid-2027. “With 378 patients enrolled and a 52-week FVC primary endpoint, ASPIRE was built to generate a high-quality dataset, and our focus remains on disciplined execution through database…” SEC filing
  • TLX, TLX597-Tx: first half of 2027. “A data readout is expected in the first half of 2027.” SEC filing
  • PDSB, PDS0301: between Q4 2026 and Q2 2028. “Near-Term Catalysts Five PDS0301 data readouts anticipated between Q4 2026 and Q2 2028 across biochemically recurrent prostate cancer, metastatic castration-resistant prostate…” SEC filing

FDA decisions:

  • IONS Hibsago (bepirovirsen): approved (2026-10-21)

Trial status changes on ClinicalTrials.gov:

  • VNDA: Phase 3 trial marked completed (2026-10-20). Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis Registry
  • GILD: Phase 2 trial marked completed (2026-10-20). Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer Registry

📄 Key SEC Filings Last Week

Filings that can move a stock, each summarized from the filing itself; financing filings are under Dilution Watch below:

  • ORIC, 2026-10-23 (clinical trial): Presented enozertinib Phase 1b data at ESMO 2026 in 1L EGFR atypical NSCLC: 84% (21 of 25) confirmed systemic ORR by investigator, 70% confirmed intracranial ORR by investigator, 88% 6-month landmark PFS, and 23% Grade 3 TRAEs with none Grade 4 or 5. Plans a global Phase 3 trial in 1H 2027. SEC filing
  • MGNX, 2026-10-23 (clinical trial): MacroGenics reported interim Phase 1 data for MGC026 at ESMO: 27% best overall response rate (6/22) in heavily pretreated SCCHN patients, with no treatment-related discontinuations in that group. A front-line SCCHN expansion with pembrolizumab is planned for early 2027. SEC filing
  • IONS, 2026-10-23 (clinical trial): Partner Roche reported Phase 3 IMAgINATION data for sefaxersen in primary IgA nephropathy, showing a statistically significant 43.1% reduction in proteinuria versus placebo at 37 weeks (95% CI: 32.5 – 52.0, P<0.0001). The safety profile was consistent with Phase 2 with no new signals. SEC filing
  • IMTX, 2026-10-23 (clinical trial): Immatics reported updated Phase 1 data for IMA203CD8, a PRAME TCR T-cell therapy, with an ORR of 51% (46/90) and cORR of 41% (36/87) across 90 efficacy-evaluable patients as of an August 7, 2026 cutoff. In 20 gynecologic patients at clinically relevant doses, ORR was 60% (12/20). SEC filing
  • GMAB, 2026-10-23 (clinical trial): Phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) met its primary PFS endpoint in platinum-resistant ovarian cancer, with HR 0.29 in the ITT population (71% risk reduction, p<0.0001) and HR 0.33 in the PAS population. Key secondary endpoint OS also met, HR 0.43 ITT (p<0.0001). No new safety signals. SEC filing
  • LNTH, 2026-10-22 (regulatory): FTC issued a Second Request on October 21, 2026, in its review of the proposed merger with Curium US Holdings LLC, extending the HSR Act waiting period. The companies expect to consummate the merger in the first half of 2027. SEC filing
  • CGTX, 2026-10-22 (regulatory): Announced written FDA feedback aligning on key elements of a Phase 3 study of zervimesine (CT1812) in dementia with Lewy bodies, including patient selection, dose, duration and endpoints. The planned study randomizes mild-to-moderate DLB patients to 100 mg once-daily oral zervimesine or placebo for nine months. SEC filing
  • BHVN, 2026-10-22 (regulatory): FDA accepted the troriluzole (Vyglxia) NDA resubmission for spinocerebellar ataxia as a complete response to the November 4, 2025 action letter, with a user fee goal date in Q1 2027. The FDA plans a Peripheral and Central Nervous System Advisory Committee meeting, date to be announced. SEC filing
  • QGEN, 2026-10-23 (deal): QIAGEN and Crown NL Bidco B.V. agreed to a tender offer for all outstanding ordinary shares at €46.50 per share in cash, under a Business Combination Agreement dated October 21, 2026. Shareholder approval resolutions are contemplated at an extraordinary general meeting. SEC filing
  • ZYME, 2026-10-23 (deal): Entered a global license and collaboration agreement with Roche for ZW209, a DLL3-targeting trispecific T cell engager. Zymeworks receives a $55.0 million upfront payment and a $40.0 million milestone on initiation of the Phase Ib Trial, plus up to $718 million in milestones and tiered royalties. SEC filing
  • BOLT, 2026-10-23 (deal): Bolt acquired Prana Therapies via stock-for-stock merger, issuing 430,746 common shares and 16,360.929 Series D preferred shares. Concurrent $120 million private placement at $8,574.30 per Series D share, plus up to $60 million from warrants, expected to fund operations into 2028. SEC filing
  • TCRT, 2026-10-23 (listing): Nasdaq closed its stockholders’ equity deficiency matter for Alaunos after confirming the company regained compliance following its October 14, 2026 private placement. The November 10, 2026 Panel hearing was cancelled and the stock stays listed on The Nasdaq Capital Market. SEC filing

💊 FDA Decisions (PDUFA Dates)

Date Ticker Drug Indication Type
2026-10-30 INO INO-3107 adults with recurrent respiratory papillomatosis (RRP) BLA
2026-11-01 AGIO mitapivat sickle cell disease sNDA

🧪 Phase 2 and 3 Trials Reaching Primary Completion

Estimated primary completion dates from ClinicalTrials.gov: the last patient reaches the main endpoint. Topline results usually follow weeks or months later.

  • NVS, 2026-10-26 (Phase 3): Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events Registry
  • VRTX, 2026-10-30 (Phase 3): A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy Registry
  • OLMA, 2026-10-31 (Phase 3): OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Registry
  • TAK, 2026-10-31 (Phase 3): TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Registry
  • CGON, 2026-11-01 (Phase 3): A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Registry
  • NAMS, 2026-11-01 (Phase 3): Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease Registry
  • IMUX, 2026-11-01 (Phase 3): Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Registry
  • IMUX, 2026-11-01 (Phase 3): Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Registry
  • HRMY, 2026-11-01 (Phase 3): An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome Registry
  • BMY, 2026-11-01 (Phase 3): A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Registry
  • SRRK, 2026-11-01 (Phase 3): Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab Registry
  • AMGN, 2026-10-31 (Phase 2): A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) Registry

📊 Earnings This Week

  • BIIB: 2026-10-28 (est. EPS 2.3722)
  • GILD: 2026-10-28 (est. EPS 2.2678)

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • NAMS: Phase 3 primary completion in 7 days, score 68/100
  • IMUX: Phase 3 primary completion in 7 days, score 64/100
  • OLMA: Phase 3 primary completion in 6 days, score 64/100

💸 Dilution Watch: New Financing Filings

  • ZLAB: private placement (8-K, 2026-10-23) EDGAR
  • IMRN: underwritten offering (424B5, 2026-10-23) EDGAR
  • HLSQ: private placement (8-K, 2026-10-23) EDGAR
  • BOLT: private placement (8-K, 2026-10-23) EDGAR
  • RCUS: underwritten offering $250M (424B5, 2026-10-22) EDGAR
  • JAGX: shelf registration (S-3, 2026-10-22) EDGAR
  • TKNO: underwritten offering $40M (424B5, 2026-10-21) EDGAR
  • NNVC: ATM program up to $2M (424B5, 2026-10-21) EDGAR
  • IRON: underwritten offering $450M (424B5, 2026-10-21) EDGAR
  • PLUR: private placement (8-K, 2026-10-20) EDGAR

Full Dilution Watch table →

📉 Downside Radar: Trading Far Below a Recent Offering

Of biotech stocks 25% or more below their close on the day of a recent offering, 76% were lower 60 trading days later, median -29% (any biotech on a random day: 53% lower, median -2%). On the radar now:

  • MDCX: $2.50, 69% below $8.15, its close on the day of its Sep 11 private placement
  • JAGX: $2.04, 66% below $6.02, its close on the day of its Sep 28 private placement
  • BKHA: $5.40, 56% below $12.19, its close on the day of its Sep 24 private placement
  • GRML: $5.78, 51% below $11.85, its close on the day of its Sep 28 registered direct offering
  • BSEM: $1.57, 49% below $3.09, its close on the day of its Sep 30 private placement
  • KZIA: $7.81, 43% below $13.77, its close on the day of its Aug 31 underwritten offering
  • HCWB: $1.17, 41% below $1.99, its close on the day of its Sep 24 private placement
  • BIAF: $2.80, 41% below $4.72, its close on the day of its Oct 9 private placement (new this week)

Full Downside Radar and how it was tested →

📉 Downside Radar: Financing Pressure

12 months of cash or less, an ATM program, shelf or S-1 on file and no offering in 90 days. Of biotech stocks in this setup, 41% sold new shares within three months (10% of comparable stocks) and 69% were lower 60 trading days later, median -17%; with 6 months of cash or less, 51% and 73%. Shortest cash first:

  • ONMD: about 0.6 months of cash (Jun 30 balance sheet), S-1 registration filed Jul 1
  • QUCY: about 0.6 months of cash (Aug 12 balance sheet), ATM program filed Oct 9
  • MTNB: about 1.3 months of cash (Jun 30 balance sheet), shelf registration filed Jun 16
  • CUE: about 2.6 months of cash (Jun 30 balance sheet), shelf registration filed Mar 16
  • BIVI: about 4.7 months of cash (Jun 30 balance sheet), ATM program filed Sep 14
  • SDEV: about 5.4 months of cash (Jun 30 balance sheet), ATM program filed Jan 20
  • PRME: about 6.8 months of cash (Jun 30 balance sheet), shelf registration filed Nov 7
  • BHVN: about 6.8 months of cash (Jun 30 balance sheet), shelf registration filed May 4

The financing-pressure list and how it was tested →

📈 Last Week’s Biggest Gainers

  • BOLT +49.64% (volume 56.1x average)
  • ESLA +37.50% (volume 4.1x average)
  • MYGN +31.59% (volume 9.7x average)
  • KRRO +29.71% (volume 3.1x average)
  • PDSB +29.10% (volume 0.6x average)

Earlier weekly catalyst recaps →

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.